Y525 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¶ó¿ì¿ùÇÇ¾Æ | Rauwolfia causing adverse effects in therapeutic use |
|
Y526 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×°íÁöÁúÇ÷Áõ ¹× Ç×µ¿¸Æ°æÈÁõ ¾à¹° | Antihyperlipidemic and antiarteriosclerotic drugs causing adverse effects in therapeutic use |
|
Y527 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸»ÃÊÇ÷°üÈ®ÀåÁ¦ | Peripheral vasodilators causing adverse effects in therapeutic use |
|
Y527 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´ÏÄÚƾ»êÀ¯µµÃ¼ | Nicotinic acid derivatives causing adverse effects in therapeutic use |
|
Y528 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×Á¤¸Æ·ùÁ¦, °æÈÁ¦ Æ÷ÇÔ | Antivaricose drugs, including sclerosing agents causing adverse effects in therapeutic use |
|
Y529 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ½ÉÇ÷°ü°èÅë¿¡ ÀÏÂ÷ÀûÀ¸·Î ¿µÇâÀ» ÁÖ´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ ¾à¹° | Other and unspecified agents primarily affecting the cardiovascular system causing adverse effects in therapeutic use |
|
Y53 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î À§Àå°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents primarily affecting the gastrointestinal system causing adverse effects in therapeutic use |
|
Y530 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â È÷½ºÅ¸¹Î H2-¼ö¿ëü±æÇ×Á¦ | Histamine H2-receptor antagonists causing adverse effects in therapeutic use |
|
Y531 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç×»êÁ¦ ¹× Ç×À§»êºÐºñÁ¦ | Other antacids and anti-gastric-secretion agents causing adverse effects in therapeutic use |
|
Y532 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÈïºÐ¼º ¼³»çÁ¦ | Stimulant laxative causing adverse effects in therapeutic use |
|
Y533 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ½Ä¿°¼ö¿Í »ïÅõÄ¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼º ¼³»çÁ¦ | Saline and osmotic laxatives causing adverse effects in therapeutic use |
|
Y534 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¼³»çÁ¦ | Other laxatives causing adverse effects in therapeutic use |
|
Y534 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â À幫±äÀ强 ¾àÁ¦ | Intestinal atonia drugs causing adverse effects in therapeutic use |
|
Y535 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼ÒÈÁ¦ | Digestants causing adverse effects in therapeutic use |
|
Y536 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Áö»çÁ¦ | Antidiarrheal drugs causing adverse effects in therapeutic use |
|
Y537 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸ÅäÁ¦ | Emetics causing adverse effects in therapeutic use |
|
Y538 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î À§Àå°èÅë¿¡ ÀÛ¿ëÇÏ´Â ±âŸ Á¦Á¦ | Other agents primarily affecting the gastrointestinal system causing adverse effects in therapeutic use |
|
Y539 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ÀÏÂ÷ÀûÀ¸·Î À§Àå°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents primarily affecting the gastrointestinal system, unspecified causing adverse effects in therapeutic use |
|
Y54 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ¼öºÐÆòÇü°ú ¹«±â¹° ¹× ¿ä»ê ´ë»ç¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents primarily affecting water-balance and mineral and uric acid metabolism causing adverse effects in therapeutic use |
|
Y540 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¤ÁúÄÚƼÄÚÀ̵å | Mineralocorticoid causing adverse effects in therapeutic use |
|